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Abstract 
Objectives: To survey time-related shifts in number of suicide-related events (SRE) during 
smoking cessation treatment with varenicline (VAR) in cases from the U.S. Food and Drug 
Administration (FDA) Adverse Event Reporting System (FAERS), as well as the characteristics of 
these shifts.  
Methods: We isolated cases from the FAERS database involving VAR usage where SRE was 
reported as an adverse event (SRE+/VAR+ case) and established a histogram of SRE+/VAR+ case 
numbers per week. Furthermore, we focused on “cases reporting specific adverse events prior to 
drug usage start” using X-bar and R chart concepts. We also attempted to exclude the influence of 
smoking history from the created histogram. Moreover, we constructed a histogram on central 
nervous system adverse events, which were frequently seen during VAR usage. 
Results: By removing the effects of smoking history, SRE onset signals were detected over a long 
period from the start of VAR use. However, expression signals for nausea and abnormal dreams 
were detected only in the early VAR administration period. 
Discussion: These results suggest that VAR use-induced SRE is expressed over a long timeframe 
from the start of treatment. Additionally, the period of SRE expression signal detection was longer 
than that of the other central nervous system adverse events (nausea and abnormal dreams). 
Therefore, SRE onset must be carefully monitored during smoking cessation treatment with VAR 
over the entire treatment period. 
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Introduction 
Smoking is a risk factor for cancer, chronic 
obstructive pulmonary disease (COPD), 
cardiovascular disease, and stroke. More than 6 
million people die every year owing to the harmful 
effects of smoking on health [1]. In Japan alone, 
smoking is responsible for medical economic and 
socio-economic losses of approximately $15 billion 
and $20 billion, respectively [2], while in the U.S., 
medical economic and socio-economic losses are 
reported to be approximately $170 billion and $156 
billion, respectively [3,4]. Smoking cessation 
treatment has a high cost-effectiveness in terms of 
preventing secondary diseases [5], and smoking 
cessation is recommended as part of a measure to 
reduce medical expenditure. 
Currently, the α4β2 nicotinic receptor partial 
agonist varenicline (Chantix®, hereinafter referred to 
as VAR), and the noradrenaline and dopamine 
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reuptake inhibitor bupropion (Zyban®) are clinically 
used as smoking cessation aids. The one-year 
abstinence rate for these drugs is 21.9% and 16.1%, 
respectively, which is higher than that for placebo [6]. 
Additionally, VAR use not only has a higher 
abstinence rate than that reported for nicotine 
replacement therapy and bupropion use, it is also less 
prone to nicotine withdrawal symptoms associated 
with smoking cessation [7, 8].  
However, in 2009, the Food and Drug 
Administration (FDA) issued a Boxed Warning that 
VAR use may induce behavioural changes such as 
depression, suicidal ideation, and suicidal behaviour 
[9]. Case-control studies and case reports indicated 
that VAR may cause neuropsychiatric events [10-12]. 
In addition, in CzeekV, the Japanese search system for 
the FDA Adverse Event Reporting System (FAERS) 
(Accessed: 2016/10/05, version 3.0.1), VAR was 
ranked at number 2 among all drugs that induce 
suicidal ideation and suicidal behaviour (bupropion 
was ranked at number 35 for suicidal ideation and 
number 37 for suicidal behaviour) [13]. However, the 
results of randomised placebo-controlled trials and 
meta-analyses did not suggest that this drug directly 
caused these events [7, 14]. Thus, the risk of VAR 
causing neuropsychiatric events, including suicide- 
related events (SRE) such as suicidal ideation and 
suicidal behaviour, depends on study design. 
However, given that a Boxed Warning has been 
issued, it is essential to take precautions regarding the 
onset of neuropsychiatric events during VAR use. 
We have already reported that VAR use 
increases SRE risk, which is the worst outcome among 
neuropsychiatric events [15]. However, the timing of 
SRE onset has not been clarified, and no studies thus 
far have discussed this. If the timing of SRE onset 
during VAR smoking cessation treatment could be 
ascertained, then SRE could be managed, which will 
be critical for the maintenance of smoking cessation.  
Therefore, we surveyed SRE onset timing during 
VAR smoking cessation treatment using cases 
reported in the FAERS database. We also surveyed 
the onset timing for other central nervous system 
adverse events such as nausea (Nau) and abnormal 
dreams (including nightmares, ABDs) [16,17], which 
occur frequently during VAR use, to investigate any 
characteristics specific to SRE onset timing in reported 
cases. 
Methods 
Data sources 
We used the FAERS database Quarterly Data 
Files (Q1 2004 to Q1 2016) published by the FDA 
(downloaded in September 2016). The Quarterly Data 
Files comprise seven types of datasets (patient 
demographic and administrative information, DEMO; 
drug/biologic information, DRUG; adverse events, 
REAC; patient outcomes, OUTC; report sources, 
RPSR; drug therapy start and end dates, THER; and 
indication for use/diagnosis, INDI). Of these, we used 
DEMO, DRUG, REAC, and THER files for analysis. 
Definition of SRE 
The following events were summarised as 
suicide related events (SRE), taken from the Medical 
Dictionary for Regulatory Activities (MedDRA, 
version 19.1) at the Preferred Term level: completed 
suicide (MedDRA code 10010144), suicidal ideation 
(10042458), suicide attempt (10042464), suicidal 
behaviour (10065604), self-injurious ideation (10051-
154), self-injurious behaviour (10063495), depression 
suicidal (10012397), intentional self-injury (10022524), 
poisoning deliberate (10036000), intentional overdose 
(10022523), and suicide threat (10077417). 
Analysis procedures 
The procedures, from accessing the Quarterly 
Data Files to the creation of a time series histogram for 
SRE reported case numbers, are shown in the 
flowchart in Figure 1 and described below. 
STEP 1. Data extraction 
We extracted only cases involving VAR usage 
from the complete set of Quarterly Data Files. We then 
extracted cases where SRE had been reported as an 
adverse event from the subset of VAR usage cases. 
STEP 2. Calculating SRE onset time 
For VAR usage cases that also reported SREs 
(SRE+/VAR+ cases), the number of days until SRE 
onset was calculated by subtracting the “VAR start 
date” from the “SRE onset date”, for cases where 
complete descriptions of both of these parameters 
were available. 
STEP 3. Correcting for VAR dosage and 
administration 
According to FDA guidelines [16], VAR dosage 
and administration should be increased gradually 
from the start of use (Days 1-3: 0.5 mg/dose once a 
day; Days 4-7: 0.5 mg/dose twice a day; Day 8 
onwards: 1.0 mg/dose twice a day). Among the 
SRE+/VAR+ cases reported to FAERS, there were 
cases where SRE onset occurred in less than 7 days 
although the reported dosage and administration was 
"1.0 mg/dose twice a day (high-dose)". Such cases 
may have reported the high-dose VAR start date (Day 
8) as START_DT, and an accurate time to SRE may not 
have been calculated. Thus, in order to evaluate SRE 
onset timing in VAR+ cases, we set the minimum 
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onset (without correction on the number of days) and 
the maximum onset (with correction on the number of 
days), and calculated the number of days to SRE onset 
in two ways: one with correction (e.g. adding 7 to the 
number of days to SRE onset in high-dose VAR cases) 
and the other without correction. 
When the number of days to SRE onset was 
corrected (i.e. the maximum onset), we divided the 
dosage and administration reported for each case into 
six patterns (A: 0.5 mg/dose once a day, B: 0.5 
mg/dose twice a day, C: 1.0 mg/dose twice a day, D: 
Starting Month Pak, E: Continuing Month Pak (Day 
29-), F: unclear or unknown), and corrected the 
number of days to SRE onset for each case based on 
the pattern. The correction methods were as follows: 
If the dosage and administration description 
pattern for a certain case was A or D, then no 
correction was made. For pattern B, 3 days were 
added to the number of days until SRE onset, for 
pattern C, 7 days were added, and for pattern E, 28 
days were added. Any cases with pattern F were 
excluded from analysis. 
When no correction was applied to the number 
of days to SRE onset (i.e. the minimum onset), we did 
not correct the number of days to SRE onset in cases 
showing patterns A to E. Cases exhibiting pattern F 
were excluded from the analysis. 
STEP 4. Eliminating comorbidity effects on suicide risk 
Psychiatric disorders such as depression and 
schizophrenia are already known as risk factors for 
suicide. Therefore, we excluded cases featuring 
concomitant antidepressant and antipsychotic agent 
usage from the SRE+/VAR+ cases [18,19]. In addition, 
to eliminate the effect of other smoking cessation aids, 
cases featuring the concurrent administration of other 
smoking cessation aids were excluded. 
STEP 5. De-duplication 
The removal of duplicated cases was 
implemented by referencing the literature on existing 
reports [20]. First, cases were removed where there 
was duplication of all items including CASE ID. Next, 
cases were removed where there were matching 
demographic data items, excluding the CASE ID. 
STEP 6. Creating histograms and removing smoking 
history effects from the SRE report 
After duplicated cases were removed, we 
created a time series histogram of the number of 
reported SRE cases per week, including cases where 
the adjusted number of days until SRE onset 
presented a negative value (Figure 1).  
Factors affecting SRE reports included not only 
“smoking cessation treatment with VAR”, but also 
“smoking history” [21]. Therefore, we focused on 
cases where the number of days until SRE onset 
presented a negative value, namely, cases where SRE 
was reported prior to VAR treatment commencement. 
These cases were not affected by “smoking cessation 
treatment with VAR” and reported SREs without the 
influence of diseases that increased suicide risk, such 
as depression and schizophrenia, due to our 
previously outlined exclusion criteria. Therefore, we 
 
Figure 1. Flowchart for time series histogram creation methodology. VAR: varenicline; SRE: suicide related events; Nau: nausea; ABDs: abnormal dreams 
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thought that these cases would be affected by 
“smoking history”. However, if the subset of cases 
that reported SRE prior to the start of VAR treatment 
was investigated, it would be possible to eliminate the 
influence of “smoking history”.  
We calculated the “mean number of cases of SRE 
reported per week +3.0 x standard deviation (SD)” for 
cases where the number of days until SRE onset was 
less than 0, referencing the Xbar and R chart concepts 
[22]. If the number of reported SRE cases in any week 
after Week 1 exceeded this value, it was determined 
that SRE incidence was affected by smoking cessation 
treatment with VAR.  
A time series histogram was created for the 
number of reported cases for each adverse event 
relating to Nau (MedDRA code 10028813) and ABDs 
(10000125, 10029412) in cases of VAR usage after data 
was extracted and processed following the same 
procedures as that used with SRE, thus also removing 
the influence of smoking history. 
Results 
SRE onset time shift in SRE+/VAR+ cases 
The number of SRE+/VAR+ cases per week is 
shown in Figure 2. The data from Week -4 to Week -1 
were related to cases where SRE was reported prior to 
start of VAR usage, and the data from Week 1 
onwards were obtained from cases where SRE was 
reported after the start of VAR treatment. 
When we corrected the number of days to SRE 
onset (i.e. the maximum onset), Week -4 to Week 12 
included 689 SRE+/VAR+ cases. The mean number of 
cases of SRE reported per week and 3.0 x SD from 
Week -4 to Week -1 were 15.0 cases and 15.3 cases, 
respectively (mean +3.0 x SD = 30.3). Thus, the 
decimal points were rounded up, and weeks with the 
number of reported SRE cases exceeding 31 after 
Week 1 were marked with * to denote weeks affected 
by smoking cessation treatment with VAR (Figure 
2A). There were a total of 9 weeks (Weeks 1 to 6 and 
Weeks 8 to 10) in which the number of reported SRE 
cases exceeded 31. 
When we did not correct the number of days to 
SRE onset (i.e. the minimum onset), 695 SRE+/VAR+ 
cases were included. The mean number of cases of 
SRE reported per week and 3.0 x SD from Week -4 to 
Week -1 were 17.0 cases and 20.0 cases, respectively. 
Thus, weeks with the number of reported SRE cases 
exceeding 38 after Week 1 were marked with * (Figure 
2B). There were a total of 5 weeks (Weeks 1 to 3, Week 
5, and Week 7) in which the number of reported SRE 
cases exceeded 38. 
Nau and ABDs onset time shift in VAR+ cases 
The number of VAR+ cases each week that 
reported on Nau (Nau+/VAR+ cases) is shown in 
Figure 3. The data from Week -4 to Week -1 were 
obtained from cases that reported Nau prior to start of 
VAR treatment, and cases that reported Nau after 
start of VAR treatment were noted Week 1 onwards. 
In the maximum onset, Week -4 to Week 12 
included 954 Nau+/VAR+ cases. The mean number 
of cases of Nau reported per week from Week -4 to 
Week -1 was 27.3 cases, and 3.0 x SD was 38.3 cases. 
Thus, weeks with the number of reported Nau cases 
exceeding 66 after Week 1 were marked with * (Figure 
3A). In each week from Week 1 to Week 3, the number 
of reported Nau cases exceeded 66. 
 
 
 
Figure 2. Number of SRE reports per week in cases undergoing smoking cessation treatment with VAR. Week -4 to Week -1 includes cases that reported SRE 
before starting smoking cessation treatment with VAR, Week 1 to Week 12 includes cases that reported SRE after starting smoking cessation treatment with VAR. 
* Indicates periods affected by smoking cessation treatment with VAR (A; ≥ 31 cases/week, B; ≥ 38 cases/week). VAR varenicline; SRE: suicide related events 
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Figure 3. Number of Nau reports per week in cases undergoing smoking cessation treatment with VAR. Week -4 to Week -1 includes cases that reported SRE 
before starting smoking cessation treatment with VAR, Week 1 to Week 12 includes cases that reported Nau after starting smoking cessation treatment with VAR. 
* Indicates periods affected by smoking cessation treatment with VAR (A; ≥ 66 cases/week, B; ≥ 79 cases/week). VAR varenicline; Nau: nausea 
 
Figure 4. Number of ABD reports per week in cases undergoing smoking cessation treatment with VAR. Week -4 to Week -1 includes cases that reported SRE 
before starting smoking cessation treatment with VAR, Week 1 to Week 12 includes cases that reported ABDs after starting smoking cessation treatment with VAR. 
* Indicates periods affected by smoking cessation treatment with VAR (A; ≥ 47 cases/week, B; ≥ 59 cases/week). VAR varenicline; ABDs: abnormal dreams 
 
In the minimum onset, Week -4 to Week 12 
included 952 Nau+/VAR+ cases. The mean number 
of cases of Nau reported per week from Week -4 to 
Week -1 was 31.0 cases, and 3.0 x SD was 47.4 cases. 
Thus, weeks with the number of reported Nau cases 
exceeding 79 after Week 1 were marked with * (Figure 
3B). In each week from Week 1 to Week 2, the number 
of reported Nau cases exceeded 79. 
The number of VAR+ cases each week reporting 
ABDs (ABDs+/VAR+ cases) is shown in Figure 4. In 
the maximum onset, Week -4 to Week 12 included 729 
ABDs+/VAR+ cases. The mean number of cases of 
ABDs reported per week from Week -4 to Week -1 
was 21.5 cases, and 3.0 x SD was 25.0 cases. Thus, 
weeks with the number of reported ABDs cases 
exceeding 47 after Week 1 were marked with * (Figure 
4A). In each week from Week 1 to Week 4, the number 
of reported ABDs cases exceeded 47. 
In the minimum onset, Week -4 to Week 12 
included 731 ABDs+/VAR+ cases. The mean number 
of cases of ABDs reported per week from Week -4 to 
Week -1 was 23.8 cases, and 3.0 x SD was 34.8 cases. 
Thus, weeks with the number of reported ABDs cases 
exceeding 59 after Week 1 were marked with * (Figure 
4B). In each week from Week 1 to Week 2, the number 
of reported ABDs cases exceeded 59. 
Discussion 
Study method validity (removal of smoking 
history influence) 
The aim of this study was to investigate SRE 
onset timing during smoking cessation treatment with 
VAR using cases reported in the FAERS database, and 
to ascertain whether the characteristics of SRE onset 
timing are different from those of other adverse 
events commonly seen in cases using VAR. 
In the maximum onset, nausea onset signals due 
to VAR use were detected only in the period from 
Week 1 to Week 3. In the minimum onset, these 
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signals were detected only in the period from Week 1 
to Week 2. Thus, it was considered that nausea due to 
VAR use was expressed only during the initial 
administration. Furthermore, smoking cessation 
treatment with VAR was considered a factor for 
nausea induction in the initial VAR administration 
period (Figure 3). 
According to the interview form [23], the 
incidence of nausea was concentrated in the 1 to 2 
week period after starting VAR usage, followed by a 
decline. Therefore, our study showed extremely 
similar results to those found in the clinical trials. This 
validates our decision to remove the influence of 
“smoking history”, making it possible to evaluate the 
effect of VAR treatment on each individual adverse 
event (SRE, nausea, and abnormal dreams). 
SRE onset timing characteristics during VAR 
treatment 
In the maximum onset, SRE onset affected not by 
smoking history but by smoking cessation treatment 
with VAR was observed in two periods: Weeks 1 to 6 
and Weeks 8 to 10. This suggests that smoking 
cessation treatment with VAR may cause SRE during 
9 weeks out of the 12 week administration period of 
VAR. However, in the minimum onset, it was 
suggested that smoking cessation treatment with VAR 
may cause SRE during 5 weeks out of 12 week 
administration period of VAR (Weeks 1 to 3, Week 5, 
and Week 7). 
In the maximum onset, the onset of nausea and 
abnormal dreams, which are central nervous system 
adverse events frequently observed during smoking 
cessation treatment with VAR, was observed only 
during the period from Weeks 1 to 3 and Weeks 1 to 4, 
respectively (Figures 3A, 4A). In the minimum onset, 
the onset of both nausea and abnormal dreams was 
observed only in the period from Week 1 to Week 2 
(Figures 3B, 4B). It was suggested that the onset of 
nausea and abnormal dreams induced during VAR 
administration was observed only during the initial 
administration. It is almost consistent with the onset 
observed in clinical trials [23]. 
Therefore, it was found that SRE observed 
during smoking cessation treatment with VAR 
showed a different expression profile than that of 
nausea and abnormal dreams, which are also central 
nervous system adverse events. Although the signal 
detection period of SRE affected by smoking cessation 
treatment with VAR varied depending on the 
presence or absence of day correction, SRE was 
expressed over a long period from the start of VAR 
administration regardless of the presence or absence 
of the correction. Thus, it was suggested that caution 
against SRE onset should always be required. 
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